Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
relevant studies Read below for studies endorsing the use of GHK-Cu
The glucagon receptor activation in retatrutide preferentially drives visceral fat loss, and waist measurement captures this before the scale does
In the STEP-1 trial published in The New England Journal of Medicine in 2021, once-weekly subcutaneous semaglutide at 2.4 mg produced a mean placebo-adjusted body weight reduction of 12.4% at 68 weeks in adults with overweight or obesity (Wilding et al., NEJM, 2021)
287 , G228G235 (2004)
US$ 20.62
US$ 20.98
US$ 21.07
US$ 29.45
US$ 29.34
US$ 29.78
